We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $9.37B
1-Year Est. Return 36.4%
This Fund
S&P 500
This Quarter Est. Return
-13.16%
1 Year Est. Return
+36.4%
3 Year Est. Return
+114.29%
5 Year Est. Return
+137.63%
10 Year Est. Return
+535.77%
AUM
$3.2B
AUM Growth
-$730M
Cap. Flow
-$164M
Cap. Flow %
-5.14%
Top 10 Hldgs %
14.44%
Holding
1,433
New
85
Increased
447
Reduced
621
Closed
196

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$7.65M
2
VZ icon
Verizon
VZ
+$4.92M
3
LIN icon
Linde
LIN
+$4.78M
4
ILMN icon
Illumina
ILMN
+$4.5M
5
AAPL icon
Apple
AAPL
+$4.21M

Sector Composition

Rank Sector Weight
1 Healthcare 13.46%
2 Technology 12.76%
3 Financials 11.37%
4 Industrials 8.31%
5 Consumer Discretionary 7.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TCRT icon
1201
Alaunos Therapeutics
TCRT
$4.79M
$65K ﹤0.01%
233
+160
+219% +$63.3K
ATAXZ
1202
DELISTED
AMERICA FIRST TAX EXEMT INV LP
ATAXZ
$64K ﹤0.01%
11,380
-6,044
-35% -$34K
SNAP icon
1203
Snap
SNAP
$9.1B
$61K ﹤0.01%
11,019
-2,000
-15% -$13K
S
1204
DELISTED
Sprint Corporation
S
$60K ﹤0.01%
10,251
PPT
1205
Franklin Premier Income Trust
PPT
$328M
$54K ﹤0.01%
+11,508
New +$56.9K
WPG
1206
DELISTED
Washington Prime Group Inc.
WPG
$54K ﹤0.01%
1,227
-489
-28% -$27.4K
IRR
1207
DELISTED
VOYA NATURAL RESOURCES EQUITY INCOME FUND
IRR
$53K ﹤0.01%
12,545
-9,959
-44% -$51.6K
ESV
1208
DELISTED
Ensco Rowan plc
ESV
$52K ﹤0.01%
3,668
-119
-3% -$3.07K
ASXC
1209
DELISTED
Asensus Surgical, Inc.
ASXC
$50K ﹤0.01%
1,692
+869
+106% +$39.5K
HIMX
1210
Himax Technologies
HIMX
$2.66B
$48K ﹤0.01%
14,240
-41,338
-74% -$195K
GPRO icon
1211
GoPro
GPRO
$122M
$44K ﹤0.01%
+10,313
New +$57.7K
PDLI
1212
DELISTED
PDL BioPharma, Inc.
PDLI
$44K ﹤0.01%
15,188
OPK icon
1213
Opko Health
OPK
$1.02B
$41K ﹤0.01%
13,514
-2,500
-16% -$8.48K
LGCY
1214
DELISTED
Legacy Reserves Inc. Common Stock
LGCY
$41K ﹤0.01%
26,725
-30,000
-53% -$96.1K
ATNM icon
1215
Actinium Pharmaceuticals
ATNM
$23.9M
$40K ﹤0.01%
3,456
-487
-12% -$8.31K
IBRX icon
1216
ImmunityBio
IBRX
$7.98B
$38K ﹤0.01%
32,600
-2,000
-6% -$4.58K
DMK
1217
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$38K ﹤0.01%
+243
New +$46.6K
RAD
1218
DELISTED
Rite Aid Corporation
RAD
$36K ﹤0.01%
2,550
-1,150
-31% -$24.3K
DBD
1219
DELISTED
Diebold Nixdorf Incorporated
DBD
$35K ﹤0.01%
13,906
-17,197
-55% -$61.7K
OIG
1220
DELISTED
Orbital Infrastructure Group, Inc. Common Stock
OIG
$32K ﹤0.01%
652
+264
+68% +$18.3K
JCP
1221
DELISTED
J.C. Penney Company, Inc.
JCP
$31K ﹤0.01%
29,400
SCU
1222
DELISTED
Sculptor Capital Management, Inc. Class A Common Stock
SCU
$29K ﹤0.01%
3,200
MIND icon
1223
MIND Technology
MIND
$46.2M
$26K ﹤0.01%
1,000
RMTI icon
1224
Rockwell Medical
RMTI
$27.4M
$26K ﹤0.01%
106
-46
-30% -$18.3K
QUIK icon
1225
QuickLogic
QUIK
$250M
$17K ﹤0.01%
1,643
-743
-31% -$9.57K

Similar funds

Oppenheimer & Co's Q4 2018 Portfolio in Review

As of Q4 2018, Oppenheimer & Co held 1,433 positions worth $3.2B, down 19% from $3.93B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Oppenheimer & Co withdrew a net $164M in Q4 2018, closing 196 positions and reducing 621 holdings. Its most notable exit was Etsy, an estimated $6.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 13% a quarter earlier, followed by Technology and Financials.

Against the trend, Oppenheimer & Co opened a new position in Linde worth $4.72M.

  • Oppenheimer & Co's largest Q4 2018 buy was Linde: 30,256 shares worth $4.72M.
  • Oppenheimer & Co added most to iShares 20+ Year Treasury Bond ETF in Q4 2018, an estimated $7.65M increase.
  • Oppenheimer & Co's biggest Q4 2018 reduction was Meta Platforms (Facebook), cutting an estimated $9.23M.
  • Oppenheimer & Co fully exited Etsy in Q4 2018, selling an estimated $6.87M.
  • Oppenheimer & Co's ten largest holdings make up 14% of its $3.2B portfolio in Q4 2018.
  • Oppenheimer & Co opened 85 new positions and closed 196 in Q4 2018.
  • Oppenheimer & Co's portfolio value fell 19% quarter-over-quarter to $3.2B.

Based on Oppenheimer & Co's 13F filing for Q4 2018, filed 29 Jan 2019.